Inside Citi’s 2013 Agriculture Outlook

Page 1 of 2

As 2012 comes to a close, Wall Street begins to look ahead to the coming year and what trends will have the biggest impact on the commodity world. Financial behemoth Citigroup Inc. (NYSE:C) recently came out with an all-encompassing forecast for the next two years for almost every major commodity. Of particular interest was their outlook on ags, as these commodities have been on a wild ride for 2012; one of the hottest summers on record and an extended drought sent futures all over the board [for more agricultural news and analysis subscribe to our free newsletter].

Citigroup Inc (NYSE:C)

Corn to Stagnate

This yellow commodity has been a favorite for traders around the industry given its laundry list of uses in our everyday lives. After this year’s less-than-optimal crop yields, corn prices surged more than 20% on the year, with the bulk of those gains coming in the summer months. Citi sees high prices holding for the first half of 2013, as there will be a lower demand for livestock feed because of smaller populations as a result of the drought. From there, the institution is predicting record planting for the rest of 2013 and 2014, which will bring prices down to a more normal level.

Wheat Will Rise

This major grain averaged $7.60/bushel this year, and Citi sees that rising to $8.60 for 2013 and cooling down to $7.75 the year after. “While the issues for the major row crops have been local and centered about the U.S. farm-belt, the buoyancy of wheat is a global phenomenon driven by disappointing production outlook and export availabilities in the Black Sea, Australia and Argentina,” Citi commented [see also The Surging Demographic Trends Behind Grain Investing].

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!